Author:
Ayestarán A.,Palma J.,Calvo F. A.
Publisher
Springer International Publishing
Reference20 articles.
1. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–43.
2. Basler L, Poel R, Schröder C, et al. Dosimetric analysis of local failures in skull-base chordoma and chondrosarcoma following pencil beam scanning proton therapy. Radiat Oncol. 2020;15(1):266.
3. Bhatt AD, Jacobson A, Lee RY, et al. High-dose proton beam-based radiation therapy in the management of extracranial chondrosarcomas. Int J Part Ther. 2017;3:373–81.
4. DeLaney TF, De Amorim Bernstein K. Proton therapy for spinal chordomas and chondrosarcomas. In: Harsh GR, Vaz-Guimaraes F, editors. Chordomas and Chondrosarcoma of the skull base and spine. 2nd ed. London: Academic Press; 2018. p. 371–82.
5. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818–31.